Today in the European Union, we can be proud and celebrate the fact that in 28 EU Member States, biosimilar medicines are in use, and competition in the biological medicines field has consistently brought value for patients and healthcare communities. In general, broader access (more patients treated) is an immediate consequence of biosimilar competition, and earlier access to treatment (where clinically appropriate) has been observed in a number of countries.
Julie Maréchal-Jamil, MScDirector, Biosimilars Policy and ScienceMedicines for Europe
Today in the European Union, we can be proud and celebrate the fact that in 28 EU Member States, biosimilar medicines are in use, and competition in the biological medicines field has consistently brought value for patients and healthcare communities. In general, broader access (more patients treated) is an immediate consequence of biosimilar competition, and earlier access to treatment (where clinically appropriate) has been observed in a number of countries.
A concern is that future access to biological therapies, including their biosimilars, has not been getting the attention it really deserves. The biological medicines portfolio set to lose exclusivity over the next decade bears little resemblance to the ones we’ve experienced thus far. Thoughtful adjustments to existing frameworks will therefore be needed to secure continuous benefits from biosimilar competition over time. Now, how do we do that?
The primary colors of a sustainable biosimilar opportunity
As with primary colors, experience has taught us that there are certain rules which, when mixed and adapted, foster different colors of a sustainable biosimilar opportunity.
When comparing and contrasting stories from EU Member States, one has to acknowledge that the disparities in stakeholder awareness, understanding, and empowerment on biosimilar medicines topics are tremendous. It is therefore by design that some countries, such as Denmark, Germany, or the United Kingdom have managed to bring all the important stakeholders onboard the biosimilar train. At the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting, held November 2-6 in Copenhagen, Denmark,1 it was striking to see that, despite 13 years of biosimilar medicines experience in the European Union, a large proportion of EU medicines agencies still lack the minimum information on these medicines, constituting the very first barrier to biosimilar adoption.
Hearing directly from some EU Member States at the recent annual European Commission multistakeholder workshop, held on October 29, 2019, it was clearly apparent that benefits can only be obtained if biosimilar medicines are used in clinical practice. Whereas in Germany, physician associations report great biosimilar uptake and evolving prescription trends, in Slovakia, the existing framework appears to disincentivise by design the use of biosimilar medicines. Stakeholders concurred in discussions that a sole focus on price erosion fails to create a conducive environment for competition in the market, as does the shift from one monopoly (originator) to another monopoly (biosimilar).
While benefit-sharing has been emulated across the European Union and internationally (eg, in Canada), it remains a rather underused policy intervention. Transparent reallocation of the biological medicines budget has been introduced in the United Kingdom and more recently in France, by means of a pilot project whereby the prescription of a selection of biosimilar medicines rewards the hospital departments involved in the prescription for reinvestment in patient care.
Obviously, when seeking the optimal shade of color, failing to combine these 3 primary colors will not deliver on the promise of earlier, broader, and future access to biological medicines and healthcare. To date, a limited number of EU Member States successfully combine trust, competition, and sense of purpose, translating into variable benefits in terms of access. In certain instances, continuous learning from experience has allowed policy frameworks to morph and get significantly ahead of the game.
The good news is that there is a lot of cumulated experience at national, regional, and local levels. Many color combinations have been tried out, and progress has been made in extending the reference color palette.
The ideas are there, the implementation is on the way, and the results should be as well where time is allowed for measures to bear fruit and where monitoring informs policy-making via feedback mechanisms.
Beyond primary colors: the political outlook, sustainability of healthcare systems, and equitable access to all medicines
The EU institutions are currently getting organised for the next 5 years, and this is an opportunity to shape future-proof biosimilar and access frameworks.
So we have a plan: earlier, broader, and future access will drive the evolution on the EU biosimilar policy framework to ensure that national healthcare systems deliver on their commitment to more equity in access to health and healthier communities.
We are planning to take the pulse on these various aspects at the occasion of our upcoming Biosimilar Medicines Conference on March 26-27, 2020, in Amsterdam; check our programme online on November 15, 2019.
Reference
1. Barbier L, Mbuaki A, Simoens S, Vulto AG, Huys I. The role of regulatory guidance and information dissemination for biosimilar medicines—the perspective of healthcare professionals and industry. Presented at: ISPOR Europe 2019; November 2-6, 2019; Copenhagen, Denmark.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.